Oxcarbazepine extended-release - Supernus Pharmaceuticals

Alternative Names: Epliga; OXC-XR; Oxcarbazepine QD; Oxtellar XR; SPN 604; SPN-804

Latest Information Update: 18 Mar 2024

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Supernus Pharmaceuticals
Class Antiepileptic drugs; Dibenzazepines; Mood stabilisers; Small molecules
Mechanism of Action Sodium channel antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

31 Dec 2023 Supernus Pharmaceuticals has patent protection for Oxcarbazepine extended-release in USA and rest of the world
31 Dec 2023 Supernus Pharmaceuticals has patent pending for Oxcarbazepine extended-release in USA
31 Dec 2020 Supernus enters into a collaboration agreement with Stendhal Mexico for commercialisation of oxcarbazepine extended release outside of the US, prior to December 2020

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com